ストックスクリーナーアプリを入手
2.975
4.49%
-0.14
前日終値:
$3.115
開ける：
$3.13
24時間の取引高:
6.38M
Relative Volume:
1.36
時価総額：
$485.09M
収益：
-
当期純損益:
$-175.43M
株価収益率:
-1.5074
EPS:
-1.9736
ネットキャッシュフロー:
$-143.28M
1週間 パフォーマンス:
-6.74%
1か月 パフォーマンス:
-2.14%
6か月 パフォーマンス:
+41.67%
1年 パフォーマンス:
+70.98%
1日の値動き範囲:
$2.8001
$3.13
1週間の範囲:
$2.8001
$3.332
52週間の値動き範囲:
$1.26
$4.23
Cabaletta Bio Inc Stock (CABA) Company Profile
Compare CABA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.975 | 485.09M | 0 | -175.43M | -143.28M | -1.9736 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-10 | 再開されました | Jefferies | Buy |
| 2024-12-20 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-02-05 | 開始されました | Jefferies | Buy |
| 2023-11-29 | 開始されました | William Blair | Outperform |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 開始されました | Stifel | Buy |
| 2023-09-05 | 開始されました | Citigroup | Buy |
| 2023-07-18 | 開始されました | Guggenheim | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-06-30 | 開始されました | Mizuho | Buy |
| 2021-01-08 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-13 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-19 | 開始されました | Cowen | Outperform |
| 2019-11-19 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Cabaletta Bio Inc (CABA) 最新ニュース
Cabaletta Bio : CABA - 24/7 Wall St.
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Price to earnings forward of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
Cabaletta Bio (CABA) Rallies 2.82% as Biotech Sector Sentiment ImprovesDip Buy Trade - dars.gov.et
Enterprise value to EBIT forward of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
Cabaletta Bio Inc (CABA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cabaletta Bio Inc. (CABA) Q1 2026 Earnings: Narrower-than-Feared Loss Drives Positive Investor SentimentManagement Guidance Update - dars.gov.et
Cabaletta Bio Inc (CABA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CABA Stock Draws Scrutiny As Ownership Filings Shift - timothysykes.com
Cabaletta Bio Inc (CABA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cabaletta Bio Inc (CABA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cabaletta Bio Inc (CABA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Certain Common Stock of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 4-JUL-2026. - marketscreener.com
Cabaletta Bio (CABA) Stock Forecast & Analyst Ratings - Moomoo
Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo
Cabaletta Bio, Inc.(NasdaqGS:CABA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2500 Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Index - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Value Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2000 Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Growth Benchmark - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 3000E Index - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell Small Cap Completeness Index - marketscreener.com
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to Russell 2500 Index - marketscreener.com
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
Cabaletta Bio, Inc. Actuals & Estimates (NASDAQ:CABA) - TradingView
CABA Forecast — Price Target — Prediction for 2027 - TradingView
CABACabaletta Bio Inc Volatility & Greeks - Finviz
Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN
Cabaletta Bio, Inc.(NasdaqGS: CABA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Cabaletta Bio Inc (CABA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cabaletta Bio Inc (CABA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cabaletta Bio Inc (CABA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup - Insider Monkey
CABA Technical Analysis & Stock Price Forecast - Intellectia AI
5 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
Cabaletta Bio Shareholders Approve Share Increase and Directors - The Globe and Mail
Cabaletta Bio (CABA) Proxy filing Summary - Quartr
Cabaletta Bio (NASDAQ: CABA) doubles authorized common shares - Stock Titan
[Form 4] Cabaletta Bio, Inc. Insider Trading Activity - Stock Titan
Director at Cabaletta Bio (CABA) receives grant of 22,000 stock options - Stock Titan
Cabaletta Bio (CABA) director receives stock options for 22,000 shares at $3.22 - Stock Titan
Cabaletta Bio | 4: Statement of changes in beneficial ownership of securities-Director Bollard Catherine - Moomoo
Cabaletta Bio (CABA) director Catherine Bollard receives 22,000 stock options at $3.22 - Stock Titan
22,000 options granted to Cabaletta Bio (CABA) director Brun - Stock Titan
Cathie Wood's ARK Invest Joins Cellares' $277 Million Series D - Business Wire
CABA: Rese-cel delivers durable, safe remissions in myositis, supporting rapid outpatient adoption - TradingView
CABA: Rese-cel shows durable, safe, drug-free responses, enabling rapid outpatient adoption and expansion - TradingView
Cabaletta Bio Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases - Yahoo Finance
Jennison Associates LLC Increases Stake in Cabaletta Bio Inc - GuruFocus
Cabaletta Bio Inc (CABA) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):